Key Highlights

• $125 Million in Gross Proceeds: Neurogene (NASDAQ: NGNE) expects roughly $125 million in gross proceeds before fees and any over-allotment exercise.

• Priced at $30.00 Per Share: The company priced 3,500,000 common shares at $30.00, signaling investor appetite for the story.

• Pre-Funded Warrant Component: Certain investors received pre-funded warrants for up to 666,666 shares, exercisable immediately at $0.000001.

Neurogene Inc. (NASDAQ: NGNE) priced a public offering that adds meaningful capital to its balance sheet. The clinical-stage company sold 3,500,000 shares of common stock at a public offering price of $30.00 per share.

In lieu of common stock, certain investors received pre-funded warrants to purchase up to 666,666 shares at a public offering price of $29.999999 per pre-funded warrant. Those warrants carry an exercise price of $0.000001 per share and are exercisable immediately.

Aggregate gross proceeds are expected to reach approximately $125 million before deducting underwriting discounts, commissions, and other offering expenses, and before any exercise of the underwriters' option to purchase additional shares.

For a clinical-stage company, a raise of this size can extend the operating runway considerably and reduce near-term financing risk. Capital lets the company fund ongoing programs, prepare for upcoming milestones, and negotiate from a stronger position.

The trade-off is dilution. Issuing new shares increases the share count and reduces existing holders' proportional ownership. That said, pricing the deal at $30.00 per share suggests healthy demand from institutional buyers, which is a constructive signal about how the market views the pipeline.

The pre-funded warrant structure is common in biotech financings. It lets certain investors participate while managing ownership limits, since the shares are effectively paid for upfront and can be exercised at a nominal price. For Neurogene (NASDAQ: NGNE), the key items to watch next are how the proceeds are deployed across its programs and whether the underwriters exercise their option for additional shares.